Happel David 4
4 · Sagimet Biosciences Inc. · Filed Feb 7, 2025
Insider Transaction Report
Form 4
Happel David
DirectorPresident & CEO
Transactions
- Award
Series A Common Stock
2025-02-06+116,000→ 755,200 total - Award
Stock Option (Right to Buy)
2025-02-06+472,000→ 472,000 totalExercise: $4.71Exp: 2035-02-05→ Series A Common Stock (472,000 underlying)
Footnotes (2)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.
- [F2]The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.